MedTrace Logo

CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

NCT00890734 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2012-02-13

No results posted yet for this study

Summary

The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.

Conditions

  • Allergic Bronchial Asthma

Interventions

DRUG

CYT003-QbG10

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Sponsors & Collaborators

  • Cytos Biotechnology AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-04-30
Completion
2010-11-30

Countries

  • Germany

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00890734 on ClinicalTrials.gov